Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Does your skin feel as dry as a desert no matter how much moisturiser you use? It's time to step up your skincare game.

Our expanding ZORYVE portfolio now encompasses psoriasis, seborrheic dermatitis, and atopic dermatitis, providing physicians ...

The unique feline dermatological cases veterinary professionals can see at the clinic, plus how to approach them ...

Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and CSU. Read why ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Learn about the benefits and risks of probiotic supplements and how to choose the best one for your health goals.

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024 Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis ...